Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.

ABSTRACT:

Objective

In patients with long-standing type 1 diabetes, we investigated whether improved beta-cell function can be achieved by combining intensive insulin therapy with agents that may 1) promote beta-cell growth and/or limit beta-cell apoptosis and 2) weaken the anti-beta-cell autoimmunity.

Research design and methods

For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial. After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab. Endogenous insulin production was determined by repeatedly measuring serum C-peptide.

Results

In 85% of individuals with long-standing type 1 diabetes who were

SUBMITTER: Rother KI 

PROVIDER: S-EPMC2782986 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature